

Date: 10.12.2024

To,

### **BSE Limited**

The Compliance Department of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001.

**Scrip Code: 531592** 

Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Press Release

Dear Sir/ Madam,

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Press Release regarding the recent agreement with Amneal Healthcare Private Limited, the details of the same is enclosed herewith.

We request you to take on record of the above.

Thanking you,

Yours faithfully,

For and behalf of the Board of Director of, Genpharmasec Limited



Mr. Sohan Chaturvedi Whole time director & CFO DIN-09629728

Encl:- as above











# Genpharmasec Limited achieves a significant milestone by entering into a Supper stockist agreement with Amneal Healthcare Private Limited.

Mumbai: Genpharmasec Limited [GENPHARMA] is pleased to announce its recent agreement with Amneal Healthcare Private Limited [AHPL].

In terms of this said Agreement, AHPL has agreed for Appointment of GENPHARMA as nonexclusive Supper Stockist within the territory to further sell to wholesale pharmacist and/or retail pharmacist the products which are manufactured by AHPL and its third-party contact manufacture or third-party licensors.

Minimum Annual Sales Commitment: AHPL undertakes to provide GENPHARMA with a minimum annual sales commitment of approximately INR 60 Crores for the period from January 1, 2025, to December 31, 2025;

## Commenting on the development Mr. Rajesh Sadhwani, Promoter and Director of Genpharmasec Limited said:

We are excited to enter into a Super Stockist Agreement with AHPL, a highly respected name in the healthcare industry. This agreement represents a key step forward in our commitment to expanding our presence in the market and strengthening our distribution capabilities. By working with AHPL, we will be able to offer an even wider range of high-quality healthcare products to our customers, ensuring greater accessibility and service excellence.

This collaboration is not only a testament to the trust and synergy between our organizations but also lays the foundation for sustained growth and mutual success in the years to come. We look forward to a fruitful partnership with AHPL and are confident that it will bring significant value to both parties.

For further information please visit www.genpharmasec.com Mr. Sohan Chaturvedi Director & CFO

Email: so han.chaturvedi@genpharmasec.com


Contact: 8655550242

### **About GENPHARMA:**

The Company was incorporated in 1992, Generic Pharmasec Limited initially started as a manufacturer and trader of organic and inorganic chemicals, dyes and pigments and from 2018 onwards the Company shifted its business activities to buying, selling and distribution of all kinds of pharmaceutical, medicinal and medicated preparations.

The Company has tied up with Abbott Point of Care Corporation INC, USA for distribution of their niche diagnostic equipment namely, i- STAT 1 Analyzer which is a hand-held blood analyzer exclusively used in ICUs and ICCUs of hospitals for immediate test results. STAT 1 Analyzer is lightweight, portable and easy to use. It operates with the advanced technology of i-STAT test cartridges. Together they create the i STAT system - a point-of-care-testing platform that provides healthcare professionals with diagnostic information when and where it is needed. The Company supplies i-STAT 1 blood Analyzers to various distributors spread all over the country. These distributors supply the same to various government as well as private hospitals in their territory.











#### **About AHPL:**

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a fully integrated, U.S.-based global leader in essential medicines, driven by a strong generics business, a growing branded portfolio, and expanding expertise in institutional injectables, biosimilars, and select international markets, including India. Founded in 2002 by brothers Chirag and Chintu Patel, Amneal was inspired by their father, Kanu Patel, an industrial pharmacist and pharmaceutical regulatory inspector in India. India holds a special significance for Amneal. Over the past 15 years, the company has invested more than \$300 million in capital and acquisitions to build a strong presence in the country. With over 5,500 employees across eight FDA-approved global manufacturing and R&D facilities, Amneal plays a pivotal role in producing high-quality medicines. In late 2022, the company reinforced its commitment to India by launching commercial operations focused on providing innovative, high-quality specialty medicines for Indian patients and families.

Disclaimer: "Some of the statements in this communication may be 'forward looking statements' within the meaning of applicable laws and regulations. Actual results might differ substantially from those expressed or implied. Important developments that could affect the Company's operations include changes in industry structure, significant changes in political and economic environment in India and overseas, tax laws, import duties, litigation and labour relations."





